From Wikipedia, the free encyclopedia
Jump to: navigation, search
Masitinib structure.svg
Clinical data
Trade names Masivet, Kinavet
AHFS/ International Drug Names
ATC code L01XE22 (WHO)
CAS Number 790299-79-5
PubChem (CID) 10074640
ChemSpider 8250179
Chemical and physical data
Formula C28H30N6OS
Molar mass 498.64 g/mol
3D model (Jmol) Interactive image

Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs.[1][2] Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.

Masitinib is being studied for several human conditions including cancers and Amyotrophic lateral sclerosis.[3][4] It is used in Europe for orphan diseases.[5]

Mechanism of action[edit]

Masitinib inhibits the receptor tyrosine kinase c-Kit which is displayed by various types of tumour.[2] It also inhibits the platelet derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR).[citation needed]


  1. ^ Hahn, K.A.; Oglivie, G.; Rusk, T.; Devauchelle, P.; Leblanc, A.; Legendre, A.; Powers, B.; Leventhal, P.S.; Kinet, J.-P.; Palmerini, F.; Dubreuil, P.; Moussy, A.; Hermine, O. (2008). "Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors". Journal of Veterinary Internal Medicine. 22 (6): 1301–1309. doi:10.1111/j.1939-1676.2008.0190.x. ISSN 0891-6640. 
  2. ^ a b Information about Masivet at the European pharmacy agency website
  3. ^
  4. ^
  5. ^ Orphan designation for Masitinib at the European pharmacy agency website